CRISPR/Cas-Based Ex Vivo Gene Therapy and Lysosomal Storage Disorders: A Perspective Beyond Cas9
Cells · 2025
DOI: 10.3390/cells14151147 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Andrés Felipe Leal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigaciones en Anomalías Congénitas y Enfermedades Raras, Universidad Icesi, Cali 760031, Colombia. Hauptthemen laut MEDLINE: Lysosomal Storage Diseases, CRISPR-Cas Systems, Genetic Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Icesi and Fundación Valle de Lili.
Abstract (Originalsprache)
Lysosomal storage disorders (LSDs) are inherited metabolic conditions characterized by lysosomal enzyme deficiencies leading to substrate accumulation. As genetic diseases, LSDs can be treated with gene therapies (GT), including the CRISPR/Cas systems. The CRISPR/Cas systems enable precise and programmable genome editing, leading to targeted modifications at specific genomic loci. While the classical CRISPR/Cas9 system has been extensively used to generate LSD disease models and correct disease-associated genetic alterations through homologous recombination (HR), recently described Cas proteins as well as CRISPR/Cas9-derived strategies such as base editing, prime editing, and homology-independent targeted integration (HITI) offer a novel way to develop innovative treatments for LSDs. The direct administration of the CRISPR/Cas9 system remains the primary strategy evaluated in several LSDs; nevertheless, the ex vivo CRISPR/Cas9-based approach has been recently explored, primarily in central nervous system-affecting LSDs. Ex vivo approaches involve genetically modifying, in theory, any patient cells in the laboratory and reintroducing them into the patient to provide a therapeutic effect. This manuscript reviews the molecular aspects of the CRISPR/Cas technology and its implementation in ex vivo strategies for LSDs while discussing novel approaches beyond the classical CRISPR/Cas9 system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centro de Investigaciones en Anomalías Congénitas y Enfermedades Raras, Universidad Icesi, Cali 760031, Colombia.
- Centro de Investigaciones Clínicas, Fundación Valle de Lili, Cali 760001, Colombia.
- Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia.
- Departamento de Genética Clínica, Fundación Valle de Lili, Cali 760001, Colombia.
ORCID-Profile: Andrés Felipe Leal, Harry Pachajoa
Förderung
- Universidad Icesi and Fundación Valle de Lili
Zitieren
APA
Leal, A. F., Prieto, L. E., & Pachajoa, H. (2025). CRISPR/Cas-Based Ex Vivo Gene Therapy and Lysosomal Storage Disorders: A Perspective Beyond Cas9. Cells. https://doi.org/10.3390/cells14151147
Vancouver
Leal AF, Prieto LE, Pachajoa H. CRISPR/Cas-Based Ex Vivo Gene Therapy and Lysosomal Storage Disorders: A Perspective Beyond Cas9. Cells. 2025. doi:10.3390/cells14151147
BibTeX
@article{Leal2025,
author = {Leal, Andrés Felipe and Prieto, Luis Eduardo and Pachajoa, Harry},
title = {CRISPR/Cas-Based Ex Vivo Gene Therapy and Lysosomal Storage Disorders: A Perspective Beyond Cas9},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14151147}
}
EUVIMED